KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2025)

Vir Biotechnology's Gains from Investment Securities history spans 8 years, with the latest figure at $9.6 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 949.12% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $7.3 million, up 32.58%, while the annual FY2025 figure was $7.3 million, 32.58% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $9.6 million at Vir Biotechnology, up from $4.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $164.3 million in Q4 2021 and bottomed at -$164.1 million in Q3 2021.
  • The 5-year median for Gains from Investment Securities is $619000.0 (2023), against an average of $7.8 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 30928.81% in 2023 before it soared 8862.12% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $164.3 million in 2021, then crashed by 32.48% to $111.0 million in 2022, then plummeted by 116.39% to -$18.2 million in 2023, then skyrocketed by 106.44% to $1.2 million in 2024, then surged by 718.69% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Gains from Investment Securities are $9.6 million (Q3 2025), $4.1 million (Q2 2025), and -$6.4 million (Q1 2025).